{"analyses":[{"ciLowerLimit":"1.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0028","paramType":"Odds Ratio (OR)","paramValue":"2.7","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.2","upperLimit":"89.6","value":"83.7"},{"groupId":"OG001","lowerLimit":"53.8","upperLimit":"75.2","value":"65.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to each treatment arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg) IV or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With Pembrolizumab (TRT B)"}],"paramType":"NUMBER","populationDescription":"ITT Pembrolizumab: Participants included in the ITT population who were stratified with the intent to receive pembrolizumab in the event of the control-arm assignment.","reportingStatus":"POSTED","timeFrame":"Baseline through Disease Progression or Death Up to 31 Months","title":"Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}